"Relying on the accumulation in the implementation of major national science and technology projects, nine covid-19 vaccines in China have been approved for conditional listing or emergency use, and have performed well in terms of output and varieties." On August 25, the National Health Commission held a press conference to introduce the progress and results of Health Science and technology innovation and medical education since the 18th National Congress of the Communist Party of China. Liu Dengfeng, inspector of the science and Education Department of the National Health Commission, said at the meeting that based on the platforms and teams of drug screening, research and development and clinical evaluation accumulated in major special projects, China has quickly promoted the successful listing of covid-19 drugs such as neutralizing antibody drugs, chemical drugs and traditional Chinese medicines. In the face of people's life and health, China's scientific and technological innovation capacity in the field of health has been significantly improved over the past decade, and a number of important scientific and technological achievements have emerged, providing strong scientific and technological support for the development of people's health undertakings and the handling of major events such as the prevention and control of COVID-19. Strive to innovate and make new drug research and development from imitation to innovation. "A new type of anticancer drug with stronger targeting, which is formed by combining antibodies and compounds, is called ADC drug. It was not available in China before and has been approved for marketing." Jiang Jiandong, President of the Institute of pharmaceutical research of the Chinese Academy of Medical Sciences and academician of the Chinese Academy of engineering, said that over the past decade, the major special projects for new drug creation have focused on the research of malignant tumor drugs, supported more than 400 projects, promoted the listing of 31 new drugs, and made tinib drugs a common anticancer drug in Chinese hospitals and exported to the United States and other countries. The creation of new drugs has not only made great progress in targeted therapy and immunotherapy, but also provided drugs with less side effects and less pain for cancer patients. "Some innovative drugs have developed new anti-cancer mechanisms. For breast cancer, lung cancer, glioma, lymphoma and other diseases, there are several drugs that can be expected to serve our patients in the next few years." Jiang Jiandong said. In terms of children's drug use, more than 600 million yuan was invested in major special projects for new drug creation, and 105 drug research projects were carried out. According to statistics, in 2021, a total of 47 children's drugs were approved for listing, of which 14 were included in the priority review and approval, which greatly promoted the listing process of children's drugs and significantly improved the level of clinical drugs. According to the data, the number of approved class I new drugs supported by the national major special projects has reached 80, 16 times that before the implementation of the special projects. Liu Dengfeng said that scientific and technological innovation has effectively promoted the leapfrog development of China's new drug research and development from imitation to innovation and the pharmaceutical industry from large to strong, and has driven the leapfrog improvement of the level of prevention, diagnosis, treatment and control of infectious diseases in China. Improve the innovation system and let the most cutting-edge technologies serve health. In the past decade, the construction of China's health science and technology innovation system has been continuously improved. 50 national clinical medical research centers have been established in 20 fields such as cardiovascular medicine, 75 national key laboratories in the field of biomedicine, and 5 medical institutions such as Beijing Union Medical College Hospital have built national major scientific and technological infrastructure for translational medicine. 109 key laboratories at the committee level have been laid out. At the same time, through the initiation and implementation of the medical and health science and technology innovation project of the Chinese Academy of Medical Sciences, a new mechanism of resource allocation stably supported by scientific research institutes was established, which promoted the standardized and healthy development of medical research in China.